Company Update 9M24
PT Kalbe Farma Tbk
October 2024
Table of Content
• | Key Updates | 04 |
• | Key Business Strategies | 07 |
• | Financial Overview | 24 |
• | Appendix 1 | 31 |
• | Appendix 2 | 38 |
Key Updates
Business Strategies
Positive Net Sales Growth Post-Pandemic
Prescription Pharmaceuticals
Building | Participation in | Dominant |
Specialty Portfolio | National Health Insurance | Market Leader |
Steadily growing specialty | Consistent growth | Leading with 13% |
category with | in E-Catalog | market share |
expanding innovative | ||
portfolio, supported by | ||
local manufacturing |
Driving Future Growth through Strategic Collaborations
Prescription Pharmaceuticals
Sustaining Business Expansion through Strategic Partnerships
Livzon Pharma Indonesia
Shareholder Agreement Signing Jul 2024
To locally manufacture more advanced pharmaceuticals ingredients for the export market, by looking at the potential for use in the domestic market in the future
Exclusive Collaboration signing May 2024
To increase market penetration and the availability of Kalbe products in the SEA, particularly Thailand
JV establishment Dec 2022
To secure raw materials, open potential future expansion in China, and reduce dependence on the use of the US dollar
Completion Dec 2022
To strengthen portfolio in focused therapeutic classes (Diabetic and Cardiovascular) and access to new category such as vaccines
Oncology
Biological-based
Other
Complete product range in all segments covering licensed, branded and unbranded generics
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |